Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | EBP | Q15125 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333252 | 0.94 | ABCB1 (0.56) | ABCB1EBPSIGMAR1TMEM97HTR1A | |
| SCHEMBL2574419 | 0.90 | HTR1A (0.52) | ABCB1EBPSIGMAR1TMEM97HTR1A | |
| SCHEMBL1333914 | 0.90 | HTR1A (0.59) | ABCB1HTR1ASLC6A4 | |
| SCHEMBL1332009 | 0.90 | HTR1A (0.52) | ABCB1EBPSIGMAR1TMEM97HTR1A | |
| SCHEMBL1332119 | 0.89 | HTR1A (0.51) | ABCB1EBPSIGMAR1TMEM97HTR1A | |
| SCHEMBL1332760 | 0.89 | HTR1A (0.50) | ABCB1EBPSIGMAR1TMEM97HTR1A | |
| SCHEMBL2574546 | 0.88 | ABCB1 (0.56) | ABCB1EBPSIGMAR1TMEM97HTR1A | |
| SCHEMBL2573352 | 0.88 | HTR1A (0.49) | ABCB1EBPSIGMAR1TMEM97HTR1A | |
| SCHEMBL2158169 | 0.88 | ABCB1 (0.53) | ABCB1EBPSIGMAR1TMEM97HTR1A | |
| SCHEMBL2569813 | 0.87 | HTR1A (0.51) | ABCB1EBPSIGMAR1TMEM97HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | ABCB1 486/4885EBP 1227/4885SIGMAR1 1/4885 |
| US-20110281890-A1 | Piperidine and piperazine derivatives | SIGMAR1, OPRM1, OPRD1 | ABCB1 591/4885EBP 1047/4885SIGMAR1 1/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | ABCB1 588/4885EBP 1097/4885SIGMAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.